Andre Goy, M.D., M.S.

Andre Goy, M.D., M.S., is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin’s disease, non-Hodgkin’s lymphoma, and HIV-associated lymphoma. As chief of John Theurer Cancer Center’s Division of Lymphoma, he leads New Jersey’s largest program for research, treatment and management of lymphoma. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris and The Pasteur Institute.

Dr. Goy was instrumental in developing the John Theurer Cancer Center’s Tissue Bank, where samples of cells, tissue, and other anatomical structures are stored and analyzed for research purposes. The Tumor Bank has received more than 1,600 patient consents since it launched.

Dr. Goy is widely-known for his work showing the first evidence of activity of bortezomib in mantle cell lymphoma and then as co-principal investigator on the PINNACLE trial, which led to the Food & Drug Administration’s approval of VELCADE® (bortezomib) for relapsed / refractory mantle cell lymphoma patients in 2006. He also took part in the original pilot study for RITUXAN® (rituximab), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders.

Dr. Goy’s research centers on developing novel targeted therapies for lymphoma and developing biomarkers for lymphoma. He has been invited to speak and teach around the world, and his research has been published extensively. He is a journal reviewer for eight medical publications that include: Blood, Clinical Cancer Research and the Journal of Clinical Oncology. 
Click here for a list of John Theurer Cancer Center Lymphoma clinical trials.

  • Medical Education: University Fourier, Grenoble, France
  • Internship and Residency: internal medicine, Grenoble University Medical Center
  • Fellowship: hematology/oncology, Grenoble University Medical Center
  • Graduate Training: M.S. in immunology, Pasteur Institute; M.S. in experimental oncology, Paris X University (University Hospitals Group of Paris, France)
  • Post-doctoral Fellowship: molecular oncology, Memorial Sloan-Kettering Cancer Center, New York City
  • Board Certifications: internal medicine, hematology, medical oncology
  • Specialization: all types of lymphoma. Lymphoma is increasing in incidence, with an 80 percent increase over the last 30 years. There are 75,000 new non-Hodgkin's lymphoma cases each year in the U.S.
  • Research Interests: lymphoma, stem cell transplantation, cellular therapy, immunology and immunotherapy, molecular epidemiology. Dr. Goy's award-winning research is being funded by several pharmaceutical companies, the Susan Vaughan Foundation for Translational Research in Lymphoma, and the U.S. Food and Drug Administration. Dr. Goy is regularly invited to speak and teach all over the world, and his research has been published extensively. He is a journal reviewer for eight medical publications, including the American Journal of Hematology and the Journal of Clinical Oncology.
  • Major Research includes:
    • developing biomarkers for lymphoma that will predict "signatures of chemoresistance or chemosensitivity" so that physicians can decide or adjust which chemotherapy agents will work most effectively in each individual patient
    • developing novel targeted therapies, typically biological agents that attack cancer cells but spare healthy tissue
    • integrating functional imaging, which helps to detect early chemoresistance in patients with lymphoma. New imaging modalities are being developed that will in the future help evaluate the impact of novel therapies in patients. Treatment can then be adjusted if needed.
  • Journal Reviewer for: Blood, Cancer, American Journal of Hematology, Leukemia and Lymphoma, Clinical Lymphoma, Clinical Breast Cancer, Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research
  • Honors/Awards: 2005 - The Maureen Fund, NJ, for Tumor Bank/Genomics Program in Ovarian Cancer and Other Tumors ($US 1,000,000) 1984 - Award for top 1% of Ranking Test post residency 
  • Memberships: American Society of Hematology, American Society of Clinical Oncology, American Medical Association


Andre Goy, MD, Chairman and Director, John Theurer Cancer Center and Chief, Division of Lymphoma, discusses the role of genetics in cancer, focusing in on advancing personalized medicine, in an interview with "Caucus: New Jersey w/ Steve Adubato."